Hippotherapy for Patients With Parkinson's Disease Aged 75 and Older

The Benefits of Hippotherapy for Patients With Parkinson's Disease of 75 Years of Age or More at Risk of Losing Their Independance.

This study tests if horse therapy can improve the quality of life for people aged 75 and older with Parkinson's disease.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 36 (estimated)
• Ages: 75 Years and up
• Sex: All
• Sponsor: Central Hospital Saint Quentin (other gov)
• Locations: 1 site (Saint-Quentin, Aisne)
• Trial ID: NCT06500182 on ClinicalTrials.gov

What this trial studies

This study evaluates the effects of hippotherapy, a nonconventional therapy using horses, on the quality of life of patients aged 75 and older with Parkinson's disease. The approach aims to enhance cognitive, sensory, and motor stimulation, thereby improving overall well-being and maintaining independence. Participants will undergo hippotherapy sessions while their quality of life is assessed using the PDQ8 scale. The ultimate goal is to demonstrate the benefits of this therapy to potentially secure coverage by social security services.

Who should consider this trial

Good fit: Ideal candidates are individuals aged 75 and older diagnosed with Parkinson's disease who are stable on their antiparkinsonian treatment.

Not a fit: Patients younger than 75 or those with atypical parkinsonian syndromes may not benefit from this study.

Why it matters

Potential benefit: If successful, this therapy could significantly improve the quality of life and autonomy of elderly patients with Parkinson's disease.

How similar studies have performed: While hippotherapy is a novel approach for Parkinson's disease, similar non-pharmacological interventions have shown promise in improving quality of life in other conditions.

Eligibility criteria

Inclusion Criteria:

* Age ≥ 75 years with PD according to Movement Disorders Society criteria (2015).
* Clinical diagnosis of Alzheimer's disease
* Has been on stable antiparkinsonian treatment for less than 3 months.
* Ability to understand the principle of the study as well as its risks.
* Written consent to participate in the trial.
* Have social insurance
* Agree to comply with all safety procedures during the study and its duration.
* Ability to understand and freely give consent
* Patient affiliated to social security or entitled beneficiary
* Autonomy preserved

Exclusion criteria :

* age \<75 years
* refusal to sign consent
* MOCA \<23
* Presence of major behavioural problems that do not allow MRI to be performed under optimal conditions
* Subjects unable to receive informed information, unable to participate in the study as a whole
* Subjects with a diagnosis of atypical parkinsonian syndrome (Lewy body disease, progressive supranuclear palsy, multisystem atrophy, cortico-basal degeneration, etc.).
* A classic contraindication to an MRI examination: claustrophobia, presence of incompatible foreign material,
* Subjects who have practised horse riding at a high level, animal phobias, wish to stop studying, etc.
* No affiliation to a social security scheme
* Antiparkinsonian treatment has not been stable for at least 3 months.
* People under protective supervision (guardianship, curatorship)
* People under family guardianship are also excluded, as are people for whom a mandate for future protection has been activated.

Where this trial is running

Saint-Quentin, Aisne

• Centre Hospitalier de Saint-Quentin; — Saint-Quentin, Aisne, France (RECRUITING)

Study contacts

• Principal investigator: Jadwiga ATTIER, PHD — CH SAINT-QUENTIN
• Study coordinator: Jadwiga ATTIER, PHD

Conditions: Parkinson Disease